Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study
Open Access
- 19 October 2018
- journal article
- research article
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 4 (4)
Abstract
Real-world studies include a broader patient population for a longer duration than randomised controlled trials (RCTs) and can provide relevant insights for clinical practice.PASSPORT was a multicentre, prospective, post-authorisation study of patients who were newly prescribed pirfenidone and followed for 2 years after initiating treatment. Physicians collected data on adverse drug reactions (ADRs), serious ADRs (SADRs) and ADRs of special interest (ADRSI) at baseline and then every 3 months.Post hocstepwise logistic regression models were used to identify baseline characteristics associated with discontinuing treatment due to an ADR.Patients (n=1009, 99.7% with idiopathic pulmonary fibrosis) had a median pirfenidone exposure of 442.0 days. Overall, 741 (73.4%) patients experienced ADRs, most commonly nausea (20.6%) and fatigue (18.5%). ADRs led to treatment discontinuation in 290 (28.7%) patients after a median of 99.5 days. Overall, 55 (5.5%) patients experienced SADRs, with a fatal outcome in six patients. ADRSI were reported in 693 patients, most commonly gastrointestinal symptoms (38.3%) and photosensitivity reactions/skin rashes (29.0%). Older age and female sex were associated with early treatment discontinuation due to an ADR.Findings were consistent with the known safety profile of pirfenidone, based on RCT data and other post-marketing experience, with no new safety signals observed.Keywords
Funding Information
- F Hoffmann-La Roche, Ltd.
This publication has 14 references indexed in Scilit:
- Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosisEuropean Respiratory Review, 2017
- Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trialsBMJ Open Respiratory Research, 2016
- Pirfenidone Post-Authorization Safety Registry (PASSPORT): Update and Concomitant Use of NAC and/or CorticosteroidsChest, 2015
- An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis: An Update of the 2011 Clinical Practice GuidelineAmerican Journal of Respiratory and Critical Care Medicine, 2015
- A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary FibrosisNew England Journal of Medicine, 2014
- Randomized controlled trials and real life studies. Approaches and methodologies: a clinical point of view.Pulmonary Pharmacology & Therapeutics, 2014
- Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trialsThe Lancet, 2011
- Clinical Course and Prediction of Survival in Idiopathic Pulmonary FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Beyond the Randomized Clinical TrialCirculation, 2008
- Idiopathic pulmonary fibrosisOrphanet Journal of Rare Diseases, 2008